Abstract
Pharmacovigilance plays a crucial role in post‐marketing surveillance of medicines and relies on the spontaneous reporting of adverse drug reactions (ADRs). Discontinuation of a drug can cause clinically relevant signs and symptoms, including withdrawal reactions; however, this subset of ADRs is not fully accommodated in current pharmacovigilance practice. We discuss proposed revisions to current ADR forms that could enhance the capture of withdrawal reaction evidence.

This publication has 17 references indexed in Scilit: